Inotiv Inc is a leading provider of preclinical and clinical research services, specializing in laboratory animal research and drug development solutions for the pharmaceutical and biotechnology industries. The company offers a wide range of scientific services, including toxicology, pathology, and pharmacology, aimed at helping clients navigate the complexities of medical research and bring new therapies to market. By leveraging advanced technologies and expertise, Inotiv supports clients in designing and executing studies that ensure the safety and efficacy of therapeutic products, thereby advancing healthcare innovation.
The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV) on behalf of Inotiv stockholders. Our investigation concerns whether Inotiv has violated the federal securities laws and/or engaged in other unlawful business practices.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inotiv, Inc. (NasdaqCM: NOTV).
